Background Sarcopenia (loss of muscle mass) is common in cirrhosis and is associated with
poor outcomes. Current teaching recommends the use of protein supplementation and …

The syndrome we refer to as Hepatic Encephalopathy (HE) was first characterized by a team
of Nobel Prize winning physiologists led by Pavlov and Nencki at the Imperial Institute of …

Hepatic encephalopathy (HE) is part of a spectrum of neurocognitive changes in cirrhosis.
HE is divided into 2 broad categories based on severity: covert hepatic encephalopathy …

Minimal hepatic encephalopathy (MHE) is an important disorder that may seriously impair
daily functioning and quality of life in patients with cirrhosis. Treatment with lactulose is of …

Minimal hepatic encephalopathy (MHE) has a negative effect on patients' daily functioning.
Thus far, no study has investigated the effect of treatment‐related improvement in cognitive …

Aliment Pharmacol Ther 2011; 33: 739–747 Summary Background The clinical classification
of hepatic encephalopathy is largely subjective, which has led to difficulties in designing …

BACKGROUND & AIMS: Hepatic encephalopathy (HE) is associated with a poor prognosis.
Lactulose is used for the treatment of HE. There is no study on the prevention of recurrence …

Hepatic encephalopathy, a challenging complication of advanced liver disease, occurs in
approximately 30–45% of patients with cirrhosis and 10–50% of patients with transjugular …

Metabolic processes utilize a variety of differing and contrasting biochemical routes to
enable synthesis of degradation and activation or deactivation of substances; in addition …

Minimal hepatic encephalopathy (MHE) is mainly diagnosed using psychometric tests such
as the psychometric hepatic encephalopathy score (PHES). Despite the clinical and social …